Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 40.09M P/E - EPS this Y - Ern Qtrly Grth -
Income -15.57M Forward P/E -0.70 EPS next Y - 50D Avg Chg -10.00%
Sales 1.88M PEG - EPS past 5Y - 200D Avg Chg -22.00%
Dividend N/A Price/Book N/A EPS next 5Y -159.60% 52W High Chg -70.00%
Recommedations 1.00 Quick Ratio 1.75 Shares Outstanding 40.30M 52W Low Chg 90.00%
Insider Own 25.54% ROA -39.64% Shares Float 25.12M Beta 0.26
Inst Own 14.34% ROE - Shares Shorted/Prior 2.20M/2.24M Price 1.03
Gross Margin 100.00% Profit Margin - Avg. Volume 47,567 Target Price -
Oper. Margin -742.20% Earnings Date Aug 9 Volume 29,740 Change 0.98%
About BeyondSpring, Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

BeyondSpring, Inc. News
11/11/24 BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
09/16/24 BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
09/16/24 BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
09/10/24 BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine
09/03/24 BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
08/31/24 Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?
08/06/24 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
08:54 AM BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year
05/16/24 BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
05/03/24 BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
04/29/24 BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
04/29/24 BeyondSpring Files 2023 Annual Report on Form 20-F
03/25/24 BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
03/06/24 Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded
02/26/24 BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
01/10/24 BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
12/18/23 BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
BYSI Chatroom

User Image big_cat777 Posted - 12 hours ago

$BYSI Let's try to bust that 4 wall again

User Image jayhwan Posted - 1 day ago

$BYSI 1불 ㅎㅇ

User Image big_cat777 Posted - 1 day ago

$BYSI Let's go. (up)

User Image michele1twits Posted - 2 days ago

$BYSI come on we are patiently waiting

User Image big_cat777 Posted - 6 days ago

$BYSI Bummer.

User Image big_cat777 Posted - 1 week ago

$BYSI What is going on here?

User Image Vamanedu Posted - 1 week ago

$BYSI $OVID 🚨💥🚀🔥 PR is incoming. $BOLT.CN $.31 (+19.23%) average volume increased ~100%. I'm going to add on Monday if it's still this low. Latest News 🚀🤑 Market cap at $5.7M; Whiting’s influence may drive upward movement if new partnerships or exploration progress 1️⃣ Bolt Metals ($BOLT.CN) advances with two key updates: Ben Whiting joins as Technical Advisor, and a C$544,500 private placement closed 💸. 2️⃣ Funding: The placement includes shares and warrants, exercisable at C$0.75 for two years, with proceeds for exploration, working capital, and copper project growth ⚒️

User Image winners18 Posted - 1 week ago

$BYSI current chemo triple combo and radio data confirms the mechanism of philibulin as dendritic cells maturing agent.

User Image winners18 Posted - 1 week ago

$BYSI accelerated pivotal single arm trial approval possible with response rate ,pfs and duration of response on 1st and 2nd line as its end point follow by a large confirmation double blind trial . The current 40 pts data could be counted towards the pivotal trial?

User Image michele1twits Posted - 1 week ago

$BYSI https://ca.finance.yahoo.com/news/beyondspring-presents-updated-efficacy-results-130000539.html In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of ...

User Image PenkeTrading Posted - 2 weeks ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of BeyondSpring Inc. Is that bullish or bearish? $BYSI #BeyondSpring #RsiOversold #NASDAQ

User Image big_cat777 Posted - 2 weeks ago

$BYSI I want 10x for Christmas.

User Image big_cat777 Posted - 2 weeks ago

$BYSI Going the wrong way again. Geez, get it together.

User Image big_cat777 Posted - 2 weeks ago

$BYSI If you are selling today, stop it.

User Image Scan8 Posted - 2 weeks ago

$BYSI The FDA Stopped Plinabulin So More People Would Die During Covid • Now The FDA Will Be Stopped • Tick Tock ⏰ https://x.com/kylenabecker/status/1854243436276383768?s=46&t=1p5uHVtBPE_WjhnI5Vbciw

User Image Scan8 Posted - 2 weeks ago

$BYSI ✨ MAHA.. Choose a side, Choose Wisely

User Image big_cat777 Posted - 2 weeks ago

$BYSI

User Image michele1twits Posted - 2 weeks ago

$BYSI

User Image winners18 Posted - 2 weeks ago

$BYSI Abstract Number 1491 Phase 2 study of pembrolizumab (pemb) plus plinabulin (plin) and docetaxel (doc) for NSCLC patients (pts) after failure on immune checkpoint inhibitor therapy: Initial efficacy and safety results Presenting Author Yan Xu – Peking Union Medical College Hospital Authors Yan Xu, Xiaoxing Gao, Minjiang Chen, Xiaoyan Liu, Jing Zhao, Wei Zhong, Mengzhao Wang Poster Presentation Day Friday, Nov. 8 Keywords Dendritic cell, Antigen presenting cells, Clinical trial, Clinical study, T cell, Tumor antigens, Immune tolerance Primary Category Clinical Trial In Progress Presentation Type Poster Presentation Abstract Type Late-Breaking Abstract

User Image winners18 Posted - 2 weeks ago

$BYSI late break abstract at sitc clinical trial in progress! Not sure more nsclc cancer triple combo data update?

User Image Scan8 Posted - 2 weeks ago

$BYSI ✨ Meanwhile in the News. ‘The World Is Baffled 🤪’

User Image big_cat777 Posted - 2 weeks ago

$BYSI 2.20 new wall.

User Image big_cat777 Posted - 2 weeks ago

$BYSI Geez, always crickets.

User Image Scan8 Posted - 10/30/24

$BYSI 🌄 ‘The Truth Will Not Be Surpressed’

User Image big_cat777 Posted - 10/30/24

$BYSI I miss 4 dolla

User Image big_cat777 Posted - 10/29/24

$BYSI BOD, sharing is caring.

User Image Scan8 Posted - 10/29/24

$BYSI 🏦 A leading surgeon has warned that “extremely aggressive” cancers with a “different biology” are rapidly forming, spreading, and mutating into “never seen before” forms of the deadly disease in people who have been “vaccinated” for Covid. Dr. James Royle is a colorectal and general surgeon who has been working as a consultant for the UK government’s National Health Service (NHS) for 9 years slaynews.com/news/top-surge…

User Image winners18 Posted - 10/28/24

$BYSI another glue deal

User Image winners18 Posted - 10/28/24

$BYSI https://www.biospace.com/business/novartis-inks-potential-2-2b-molecular-glue-deal-with-monte-rosa

User Image winners18 Posted - 10/28/24

$BYSI

Analyst Ratings
Baird Outperform May 2, 23
Jefferies Hold Dec 2, 21
B of A Securities Underperform Dec 2, 21
HC Wainwright & Co. Neutral Dec 1, 21
HC Wainwright & Co. Buy Sep 20, 21
Baird Outperform Sep 9, 21
HC Wainwright & Co. Buy Aug 4, 21
HC Wainwright & Co. Neutral Apr 5, 21
B of A Securities Buy Jan 11, 21